A small group of patients with an otherwise incurable form of T‑cell leukemia have seen their cancer driven into remission by ...

Researchers from the Keck School of Medicine of USC have developed a new type of chimeric antigen receptor (CAR) T cell that ...

A new treatment using genome-edited immune cells, developed by scientists at UCL (University College London) and Great Ormond ...

Safety and efficacy data from a phase 1 multicenter study evaluating rapcabtagene autoleucel, an investigational ...

Automated TCR-T production streamlines personalized immunotherapy, reducing patient burden and improving engineered T cell quality.

CAR T-cell therapy, which transforms patients’ own immune cells into cancer-fighting warriors, has been extremely effective ...

CHICAGO — Rosnilimab, a novel pathogenic T-cell depleting drug, met its primary endpoint of changes in DAS28 C-reactive ...

CAR-T stands for Chimeric Antigen Receptor T-cell therapy. Doctors harvest the patient’s T cells, the soldiers of the immune ...

Safety and efficacy data from a phase 1 multicenter study evaluating rapcabtagene autoleucel, an investigational ...

Patients who receive T-cell redirecting therapies are typically hospitalized for several days after treatment to watch for ...

Measuring the lymphocytes - white blood cells that fight infection - in a patient's blood can be used to predict outcomes in ...

Erythropoietin, the protein that drives red blood cell formation, also induces tolerance in dendritic cells, leading to the development of regulatory T cells.